LATE-BREAKING ABSTRACT: Benralizumab reduces exacerbations in severe, uncontrolled asthma: Results of the phase III CALIMA trial Source: International Congress 2016 – Late-breaking topics in airways disease Year: 2016
LATE-BREAKING ABSTRACT: Benralizumab for mild to moderate, persistent asthma: The BISE phase III study Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives Year: 2016
LATE-BREAKING ABSTRACT: LAVOLTA I and II: Results of 2 phase III studies to assess the efficacy and safety of lebrikizumab in patients with uncontrolled asthma Source: International Congress 2016 – Late-breaking topics in airways disease Year: 2016
LATE-BREAKING ABSTRACT: Anti-interleukin-5 in severe asthma: Blood eosinophilia predicts lung function improvement Source: Annual Congress 2013 –Origins and diagnosis of asthma Year: 2013
LATE-BREAKING ABSTRACT: Multinational, database cohort study to assess severe exacerbation rate in asthma Source: International Congress 2015 – Asthma and COPD: overlap and exacerbations Year: 2015
Reproducibility and stability of severe asthma research program (SARP) clinical cluster phenotypes in SARP3 Source: International Congress 2016 – Phenotyping asthma Year: 2016
Tiotropium for uncontrolled asthma (a meta-analysis) Source: Annual Congress 2013 –Treatment of asthma Year: 2013
Comparison of clinical features of severe persistent asthma and refractory asthma Source: Annual Congress 2013 –Phenotyping asthma: clinical severity, comorbid conditions response to treatment? Year: 2013
LATE-BREAKING ABSTRACT: Early identification of responders to reslizumab at 16 weeks using an algorithm derived from the pivotal clinical studies of severe eosinophilic asthma (SEA) patients Source: International Congress 2016 – Recent high impact findings regarding COPD comorbidities Year: 2016
LATE-BREAKING ABSTRACT: The analysis of the severe asthma prevalence rate in China Source: International Congress 2016 – Prevalence of obstructive airway diseases, methods of diagnosis, and lung function testing Year: 2016
QAW039 (fevipiprant) improves lung function and control of asthma symptoms in patients with more severe air flow limitation: A proof-of-concept study Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015
LATE-BREAKING ABSTRACT: Disease control rate (DRC) of bronchial asthma during pregnancy Source: Annual Congress 2013 –Diagnosis and management of respiratory diseases Year: 2013
An extensive function evaluation in severe asthma with airflow limitation Source: International Congress 2014 – Asthma: still a heterogeneous condition! Year: 2014
The asthma-COPD, overlap syndrome, our clinical experience Source: International Congress 2014 – Asthma or COPD: comorbid condition or a poorly understood single disease? Year: 2014
Childhood obesity in relation to poor asthma control and exacerbations Source: International Congress 2016 – Paediatric asthma: lessons learned from studies with large sample sizes and multi-centre drug studies Year: 2016
Correlation between meteo-climatological factors and asthma exacerbation among children: A prospective study Source: International Congress 2016 – Living with asthma around the globe Year: 2016
Work related symptoms of adult patients with asthma: A multicenter, national, questionnaire based study Source: International Congress 2015 – Work, environment and the epidemiology of asthma Year: 2015
LATE-BREAKING ABSTRACT: Vocal cord dysfunction (VCD) in mild and severe asthma Source: International Congress 2016 – Features and impact of comorbidities in COPD Year: 2016
What is important to people with asthma: Maximising research impact? Source: International Congress 2015 – Any news from the asthma field? Year: 2015
Prevalence of refractory asthma in population with severe asthma Source: International Congress 2016 – Phenotyping and monitoring airway diseases Year: 2016